Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2050706 | 1.00 | OPRM1 (0.43) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL4672395 | 0.82 | ITGB3 (0.40) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL981047 | 0.82 | ITGB3 (0.40) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL3408615 | 0.79 | ESR1 (0.45) | OPRM1OPRK1OPRD1CYP2D6TSHR | |
| SCHEMBL2786598 | 0.78 | ITGB3 (0.52) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL2786534 | 0.78 | ITGB3 (0.52) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL2046087 | 0.75 | OPRM1 (0.40) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL2048375 | 0.75 | OPRM1 (0.40) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL2045113 | 0.75 | OPRM1 (0.40) | OPRM1OPRK1OPRD1ITGB3ITGA2B | |
| SCHEMBL538079 | 0.72 | ITGB3 (0.39) | OPRM1OPRK1OPRD1ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2329821-A1 | Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema | GlaxoSmithKline LLC (US) | 2011-06-08 | — | — | EP | disclosed |